Share Issue Gives Cellectricon SEK 89 Million to Continue Its Rapid Market Expansion
Posted on: Thursday, 21 February 2008, 09:01 CST
GOTHENBURG, Sweden, February 21 /PRNewswire/ -- With two successful international product launches, Swedish biotech firm Cellectricon is entering a new expansion phase. The share issue will strengthen Cellectricon's financial capacity prior to a number of significant product launches in 2008-2009. These products have been developed in close collaboration with leading global pharmaceutical companies to meet the industry's increasing demand for fully automated, highly efficient systems for pre-clinical pharmaceutical development.
"Cellectricon is now entering a new expansion phase, in which the company will soon launch two large-scale systems that will revolutionize drug discovery. This capital will enable us to continue our rapid expansion in the United States, Europe, and Asia," said Dr. Mattias Karlsson, Cellectricon's CEO.
In 2008 Cellectricon will launch the first of their large-scale screening system, Cellaxess(R)HT, which has been developed in close cooperation with one of the world's largest pharmaceutical companies. Cellaxess(R)HT will be the only system on the market that enables large-scale supply of genetic material for cells and is tailor made for high throughput RNAi screening.
About Cellectricon
Cellectricon AB is a Swedish biotech company that is a successful provider of groundbreaking products to the pharmaceutical industry that increase efficiency in pre-clinical pharmaceutical development. Cellectricon has already successfully launched two products onto the market that have been sold to ten of the 12 largest pharmaceutical companies in the world. In 2007 the company increased its revenue by almost 50%. In 2008-2009 launch the high-performance systems Cellaxess(R)HT for RNAi screening and Dynaflow(R)HT for ion channel screening. Cellectricon's forthcoming products address a market that is estimated to be US $1.4 billion by 2010.
Cellectricon AB
CONTACT: For more information, contact: Susanne Fagerlund, VP MarketCommunications, Telephone: +46(0)31-760-35-15, E-mail:susanne.fagerlund@cellectricon.com
Source: PRNewswire
Related Articles
- Growing Demand for Rapid Screening and Detection Systems Pushes the European Maritime Security Market, Finds Frost & Sullivan
- Green Machines: Worldwide Solar Manufacturing Capacity, Production, and Capacity Utilization Market Shares, Forecasts, and Strategies, 2008-2014
- Zila's Oral Cancer Screening Product, ViziLite Plus, Featured at BDTA Dental Showcase in London
- Zila to Market Its Proprietary Oral Cancer Screening Product, ViziLite Plus, in Russia
- Zila Adds Four Major European Markets for Its Proprietary Oral Cancer Screening Product, ViziLite Plus
- Zila to Begin Distributing Its Proprietary Oral Cancer Screening Product, ViziLite Plus, in Greece
- Research and Markets: IMCOR Pharmaceutical Co - Product Pipeline Report Now Available
- Research and Markets: DUSA Pharmaceuticals Inc - Product Pipeline Report Available Now
- CytoCore, Inc. Announces New Cancer Screening and Treatment System On The Horizon
- IDC Releases Vendor Shares in Relational and Object-Relational Database Management Systems Software Market for 2003
 |
 |
User Comments (1)
| 1. |
Posted by razak on 06/28/2009, 21:55 hai |
RSS Feeds